Sialix
Latest round
- Series B
Last raised
- Feb 2014
Total raised
- $2.2M
Investors
- 6
About Sialix
Sialix, Inc.Founded in 2006 and headquartered in Newton, US, Sialix, Inc. specializes in supplying vital reagents for life sciences research.Sialix Cancer Research specializes in the development and supply of monoclonal antibodies, polyclonal antibodies, and recombinant lab reagents designed for research applications in the life sciences sector. Their primary offerings cater to the needs of laboratories engaged in cancer research, immunology, and serological testing, particularly in the context of diseases like Chagas disease. The company’s products are utilized in various assays, including enzyme-linked immunosorbent assays (ELISAs), providing researchers with critical tools for diagnostic testing and therapeutic development.Sialix Cancer Research generates revenue through direct sales of their specialty reagents and antibodies to research laboratories and medical institutions. The company employs a B2B transaction model where clients place orders based on specific research needs, often benefiting from tailored solutions that address their unique project requirements. Pricing structures are established for individual products, with potential for bulk purchasing agreements for larger institutions, facilitating a steady flow of recurring revenue. The company's flagship products, particularly its monoclonal antibodies and customized ELISA kits, play a crucial role in securing contracts with laboratories focused on cancer diagnostics and treatment.Sialix, Inc. aims to expand its product line by launching new monoclonal antibodies tailored for emerging cancer research needs, with releases planned for late 2024. In addition, the company is targeting expansion into the Asian markets, specifically China and Japan, by 2025.53 mn will be utilized to support these product developments and market entry strategies.
Who invested in Sialix
6 investors across 2 rounds
See all investors in Sialix
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Sialix
Who invested in Sialix?
Sialix has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sialix raised?
Sialix has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Sialix last raise money?
Sialix's most recent round on record is a Series B, in Feb 2014.
What does Sialix do?
Sialix is a pharmaceuticals company.
Where is Sialix headquartered?
Sialix is headquartered in Newton, US.
Which VCs invest in companies like Sialix?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Sialix's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Sialix? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.